Recent developments in lymphoma and myeloma will be presented at the upcoming Lymphoma & Myeloma 2016: An International Congress on Hematologic Malignancies, Oct. 13-15, in New York. More than 40 internationally recognized leaders in biology, immunology, pathology, and translational and clinical research will provide guidance and expertise about the latest advances in basic science, translational medicine, and clinical trials.
The congress organized by Imedex is chaired by Drs. Morton Coleman, Ruben Niesvizky, John P. Leonard, and Richard R. Furman, all of Weill Cornell Medicine at Cornell University. Participants from nearly 50 counties will attend the three-day educational event filled with interdisciplinary approaches, debates, special lectures, and interactive techniques to explore developments regarding diseases including Hodgkin’s disease, chronic lymphatic leukemia, and Waldenstrom’s macroglobulinemia in addition to myeloma and lymphoma.
This year’s event marks the first time that the Lymphoma Research Foundation is partnering with Imedex to provide a one-day continuing education conference called the National Lymphoma Rounds immediately following Lymphoma & Myeloma 2016. Specifically planned to highlight breaking news in lymphoma, the separate professional crediting event will be Sunday, Oct. 16.
“With the Lymphoma Research Foundation’s National Lymphoma Rounds occurring the day after our session on lymphoma, I am extraordinarily pleased to be able to provide two days of outstanding presentations covering the entire scope of what is new and exciting in lymphoma,” Coleman, chairman of the Lymphoma & Myeloma event and program chair of the New York Lymphoma Rounds of the Lymphoma Research Foundation, said in a press release. “These sessions should be valuable to both researchers and clinicians, and should provide a unique format for the exchange of ideas.”
Leonard, co-chair of the organization and past chair of the research foundation, is also excited about the collaboration.
“The Lymphoma Rounds program is an exciting addition to our sessions, and will no doubt be a great venue for community physicians and lymphoma specialists alike to discuss both routine patient management options and challenging cases,” Leonard said.
